PBA
PRTA icon

Paradigm Biocapital Advisors’s Prothena Corp PRTA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio PRTA Stock Details PRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-75,000
Closed -$4.52M – 28
2022
Q4 		$4.52M Sell
75,000
-160,826
-68% -$9.42M 0.53% 23
2022
Q3 		$14.3M Buy
+235,826
New +$7.46M 1.91% 18
2022
Q2 		– Sell
-267,946
Closed -$9.8M – 27
2022
Q1 		$9.8M Buy
+267,946
New +$9.66M 2.59% 17

Other funds holding PRTA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Paradigm Biocapital Advisors's PRTA Position: Q1 2023 in Review

Paradigm Biocapital Advisors sold out of Prothena Corp (PRTA) in Q1 2023, closing a stake of 75,000 shares — an estimated $4.52M sold.

Paradigm Biocapital Advisors first reported a position in PRTA in Q1 2022 and held it in 3 quarters. The position peaked at $14.3M in Q3 2022. 191 funds tracked by Wall St. Rank hold PRTA as of Q1 2023.

  • Paradigm Biocapital Advisors reported no remaining Prothena Corp position as of Q1 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 75,000 Prothena Corp shares in Q1 2023, an estimated $4.52M.
  • Paradigm Biocapital Advisors first reported a position in Prothena Corp in Q1 2022 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's Prothena Corp position peaked at $14.3M in Q3 2022.
  • 191 funds tracked by Wall St. Rank held Prothena Corp as of Q1 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2023, filed 15 May 2023.